Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SEATTLE and SOUTH SAN FRANCISCO, Calif., April 20, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that new and updated data from two ongoing clinical trials of CMB305 and G100, as well as translational data examining the association of immunological response with improved survival in CMB305 and LV305 patients, will be presented in an oral and two posters presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 - 6, 2017 in Chicago. The ASCO presentation details are as follows:
ORAL PRESENTATION
Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS)
| Abstract # 11006 |
| Session Title: Sarcoma |
| Date: Friday, June 2, 2017 |
| Time: 3 p.m. – 6 p.m. CT (oral session) |
| Location: S100bc |
| Presenter: Neeta Somaiah, M.D., Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center |
POSTER PRESENTATIONS
The Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients
| Abstract # 3090 |
| Session Title: Developmental Therapeutics—Immunotherapy |
| Date: Monday, June 5, 2017 |
| Time: 8 a.m. – 11:30 a.m. CT (poster session) |
| Location: Hall A |
| Presenter: Seth M. Pollack, M.D., Fred Hutchinson Cancer Research Center |
Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma
| Abstract # 7537 |
| Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia |
| Date: Monday, June 5, 2017 |
| Time: 8 a.m. – 11:30 a.m. CT (poster session) |
| Location: Hall A |
| Presenter: Christopher Flowers, M.D., Department of Hematology and Medical Oncology, Emory University School of Medicine |
Additional data than those included in the abstracts may be included in the presentations.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary foci of Immune Design's ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex and GLAAS, the fundamental technologies of which were licensed from the California Institute of Technology and the Infectious Disease Research Institute (IDRI), respectively. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Immune Design's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Immune Design's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Immune Design's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Immune Design assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Media Contact Julie Rathbun Rathbun Communications [email protected] 206-769-9219 Investor Contact Shari Annes Annes Associates [email protected] 650-888-0902
